Knockdown of AGR2 induces cellular senescence in prostate cancer cells

Carcinogenesis

Volumn 33, Issue 6, 2012, Pages 1178-1186

  Hu, Zhongyi ^a   Gu, Yuanyuan ^a   Han, Bo ^a   Zhang, Jinsan ^b   Li, Zunling ^a   Tian, Keli ^a   Young, Charles Y F ^b   Yuan, Huiqing ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; BETA GALACTOSIDASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE H2AX; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRIMETHYLHISTONE H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; BETA-GALACTOSIDASE; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE CELL CYCLE CHECKPOINTS; HISTONES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATE; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84864304345     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs141     Document Type: Article

References (50)

1. Jemal,A. et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Sarkar,F.H. et al. (2010) Novel targets for prostate cancer chemoprevention. Endocr. Relat. Cancer, 17, R195-R212.
3. Shih,L.J. et al. (2007) Characterization of the agr2 gene, a homologue of X. laevis anterior gradient 2, from the zebrafish, Danio rerio. Gene Expr. Patterns, 7, 452-460.
4. Zhao,F. et al. (2010) Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. Dev. Biol., 338, 270-279.
5. Park,S.W. et al. (2009) The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl Acad. Sci. USA, 106, 6950- 6955.
6. Pohler,E. et al. (2004) The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell. Proteomics, 3, 534-547.
7. Park,K. et al. (2011) AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp. Mol. Med., 43, 91-100.
8. Wang,Z. et al. (2008) The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res., 68, 492-497.
9. Liu,D. et al. (2005) Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res., 65, 3796-3805.
10. Zhao,L. et al. (2009) Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res., 69, 7696-7703.
11. Vanderlaag,K.E. et al. (2010) Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res., 12, R32.
12. Innes,H.E. et al. (2006) Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br. J. Cancer, 94, 1057-1065.
13. Fritzsche,F.R. et al. (2006) Prognostic relevance of AGR2 expression in breast cancer. Clin. Cancer Res., 12, 1728-1734.
14. Shen,D. et al. (2005) Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem. Biophys. Res. Commun., 326, 218-227.
15. Bu,H. et al. (2011) The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate, 71, 575-587.
16. Zhang,Y. et al. (2010) ErbB3 binding protein 1 represses metastasispromoting gene anterior gradient protein 2 in prostate cancer. Cancer Res., 70, 240-248.
17. Maresh,E.L. et al. (2010) Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer, 10, 680.
18. Zhang,Y. et al. (2007) Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis., 10, 293-300.
19. Zhang,J.S. et al. (2005) AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer, 43, 249- 259.
20. Zhu,H. et al. (2007) High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett., 245, 303-314.
21. Fritzsche,F.R. et al. (2007) Expression of AGR2 in non small cell lung cancer. Histol. Histopathol., 22, 703-708.
22. Riener,M.O. et al. (2009) Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma. Histol. Histopathol., 24, 1121-1128.
23. Lee,S. et al. (2006) Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol. Rep., 16, 747-754.
24. Vivekanandan,P. et al. (2009) Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum. Pathol., 40, 293-299.
25. Lepreux,S. et al. (2011) Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree. Liver Int., 31, 322-328.
26. Barraclough,D.L. et al. (2009) The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am. J. Pathol., 175, 1848-1857.
27. Wu,Z.S. et al. (2008) Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance. Zhonghua Bing Li Xue Za Zhi, 37, 109-113.
28. Ewald,J.A. et al. (2010) Therapy-induced senescence in cancer. J. Natl Cancer Inst., 102, 1536-1546.
29. Lleonart,M.E. et al. (2009) Senescence induction; a possible cancer therapy. Mol. Cancer, 8, 3.
30. Zeng,J. et al. (2010) The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology, 138, 981-992.
31. Larsson,L.G. (2011) Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin. Cancer Biol., 21, 367-376.
32. Yu,Y.P. et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol., 22, 2790-2799.
33. Kuilman,T. et al. (2010) The essence of senescence. Genes Dev., 24, 2463- 2479.
34. Campisi,J. et al. (2007) Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol., 8, 729-740.
35. Young,A.P. et al. (2008) VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol., 10, 361-369.
36. INK4a. Cell, 88, 593-602.
37. Shay,J.W. et al. (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene, 23, 2919-2933.
38. Liu,S. et al. (2011) The PI3K-Akt pathway inhibits senescence and promotes self-renewal of human skin-derived precursors in vitro. Aging Cell, 10, 661-674.
39. Ramachandran,V. et al. (2008) Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res., 68, 7811-7818.
40. Brychtova,V. et al. (2011) Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett., 304, 1-7.
41. INK4a expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J. Clin. Oncol., 21, 3328-3334.
42. Han,E.K. et al. (1998) Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate, 35, 95-101.
43. CIP1, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology, 42, 519- 523.
44. Braig,M. et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 436, 660-665.
45. Chen,Z. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436, 725-730.
46. Jee,H.J. et al. (2010) Nek6 overexpression antagonizes p53-induced senescence in human cancer cells. Cell Cycle, 9, 4703-4710.
47. Zweitzig,D.R. et al. (2007) Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol. Cell. Biochem., 306, 255-260.
48. Dong,A. et al. (2011) The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J. Biol. Chem., 286, 18301-18310.
49. Kennedy,A.L. et al. (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol. Cell, 42, 36-49.
50. Lorenzini,A. et al. (2002) Role of the Raf/MEK/ERK and the PI3K/ Akt(PKB) pathways in fibroblast senescence. Exp. Gerontol., 37, 1149- 1156.